Stephen Hoge Sells 318 Shares of Moderna, Inc. (NASDAQ:MRNA) Stock

Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge sold 318 shares of Moderna stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $76.99, for a total transaction of $24,482.82. Following the completion of the transaction, the president now owns 1,443,002 shares of the company’s stock, valued at $111,096,723.98. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Stephen Hoge also recently made the following trade(s):

• On Thursday, August 29th, Stephen Hoge sold 300 shares of Moderna stock. The shares were sold at an average price of $78.03, for a total value of $23,409.00.
• On Monday, August 12th, Stephen Hoge sold 254 shares of Moderna stock. The stock was sold at an average price of $84.10, for a total value of $21,361.40.
• On Monday, July 15th, Stephen Hoge sold 15,000 shares of Moderna stock. The shares were sold at an average price of $121.12, for a total value of $1,816,800.00.
• On Monday, June 17th, Stephen Hoge sold 15,000 shares of Moderna stock. The stock was sold at an average price of $138.16, for a total transaction of $2,072,400.00.

Moderna Stock Up 1.3 %

Shares of NASDAQ:MRNA opened at $73.44 on Friday. The stock has a market capitalization of $28.15 billion, a P/E ratio of -4.69 and a beta of 1.67. The stock’s 50-day moving average price is $101.13 and its 200-day moving average price is $112.69. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05. Moderna, Inc. has a 12-month low of $62.55 and a 12-month high of $170.47.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, topping analysts’ consensus estimates of ($3.47) by $0.14. The business had revenue of $241.00 million for the quarter, compared to analysts’ expectations of $128.41 million. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The business’s quarterly revenue was down 29.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($3.62) EPS. On average, equities analysts anticipate that Moderna, Inc. will post -9.52 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on MRNA shares. Hsbc Global Res raised shares of Moderna from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 28th. HSBC upgraded Moderna from a “reduce” rating to a “hold” rating and set a $82.00 price objective on the stock in a research report on Wednesday, August 28th. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research report on Thursday, August 1st. Piper Sandler reaffirmed an “overweight” rating and issued a $157.00 price target (down previously from $214.00) on shares of Moderna in a report on Friday, August 2nd. Finally, Evercore ISI reissued an “in-line” rating and set a $120.00 price objective on shares of Moderna in a report on Thursday, June 27th. Ten investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, Moderna presently has a consensus rating of “Hold” and an average target price of $123.79.

Hedge Funds Weigh In On Moderna

Hedge funds have recently modified their holdings of the company. Ashton Thomas Private Wealth LLC purchased a new position in Moderna during the 2nd quarter valued at about $26,000. Ogorek Anthony Joseph NY ADV purchased a new position in shares of Moderna during the fourth quarter valued at approximately $27,000. Family Firm Inc. purchased a new position in shares of Moderna during the second quarter valued at approximately $33,000. Cedar Wealth Management LLC raised its holdings in shares of Moderna by 45.0% during the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after acquiring an additional 90 shares in the last quarter. Finally, Westside Investment Management Inc. purchased a new stake in Moderna in the first quarter worth $32,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.